Aaron Lorenzo

Aderis Drug Slows Ventricular Rate In Atrial Fibrillation Study

Nov. 12, 2003

By Aaron Lorenzo

Aradigm Adds To Cash Position With $13.5M Private Placement

Nov. 12, 2003

By Aaron Lorenzo

Agencourt Awarded $27M For Sequencing Project Selection

Nov. 10, 2003

By Aaron Lorenzo

Agencourt Awarded $27M For Sequencing Project Selection

Nov. 10, 2003

By Aaron Lorenzo

Climbing Through The Window: Pharmion, NitroMed Price IPOs

Nov. 7, 2003

By Aaron Lorenzo

The industry increased its number of publicly traded companies Thursday as Pharmion Corp. and NitroMed Inc. priced their initial public offerings. (BioWorld Today)

Climbing Through The Window: Pharmion, NitroMed Price IPOs

Nov. 7, 2003

By Aaron Lorenzo

The industry increased its number of publicly traded companies Thursday as Pharmion Corp. and NitroMed Inc. priced their initial public offerings. (BioWorld Today)

NeuroMed Gets $32M In Third Round To Push Pain Product

Nov. 5, 2003

By Aaron Lorenzo

NeuroMed Gets $32M In Third Round To Push Pain Product

Nov. 5, 2003

By Aaron Lorenzo

CV Therapeutics Stock Drops On Ranexa Approvable Letter

Nov. 3, 2003

By Aaron Lorenzo

CV Therapeutics Inc. received a mixed bag of news related to Ranexa, its lead compound for chronic angina, and investors took the news badly as the company's stock slipped 21.7 percent Friday. (BioWorld Today)

CV Therapeutics Stock Drops On Ranexa Approvable Letter

Nov. 3, 2003

By Aaron Lorenzo

CV Therapeutics Inc. received a mixed bag of news related to Ranexa, its lead compound for chronic angina, and investors took the news badly as the company's stock slipped 21.7 percent Friday. (BioWorld Today)